Extended‐release methylphenidate vs placebo
Serious adverse events Median · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
1 finding from 1 review
- Extended‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults 2022 · Cochrane Headline outcomes only1.43 [0.85, 2.43]14 studies · 4078 participantsVery low